Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov;33(11):1126-1133.
doi: 10.1089/AID.2015.0340. Epub 2017 Jun 26.

Association of Tuberculosis Status with Neurologic Disease and Immune Response in HTLV-1 Infection

Affiliations

Association of Tuberculosis Status with Neurologic Disease and Immune Response in HTLV-1 Infection

Anselmo Souza et al. AIDS Res Hum Retroviruses. 2017 Nov.

Abstract

The human T cell lymphotropic virus type 1 (HTLV-1) is the etiologic agent of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HTLV-1 infected individuals have increased susceptibility to Mycobacterium tuberculosis infection but the influence of tuberculosis (TB) on the course of HTLV-1 infection is unknown. The aim of this study was to evaluate the influence of TB on immunological, virologic, and neurologic features of HTLV-1 infection. This is a retrospective analysis of individuals enrolled in a cohort study from an HTLV-1 clinic who were evaluated for past or latent tuberculosis (LTB) and classified clinically as HTLV-1 carriers, probable HAM/TSP and definite HAM/TSP. Spontaneous cytokine production (interferon-gamma [IFN-γ], tumor necrosis factor [TNF], and interleukin[IL]-10), serum chemokines (CXCL9 and CXCL10) and HTLV-1 proviral load were evaluated. Of 172 participants, 64 did not have histories of TB (TB- group), 81 had LTB and 27 had TB in the past (TB+ group). In the TB+ group, there was a higher frequency of HAM/TSP patients (35%) than in HTLV-1 carriers (10%) (OR = 3.8, p = .0001). HAM/TSP patients with histories of TB had higher IFN-γ/IL-10 and TNF/IL-10 ratios when compared with HAM/TSP patients without histories of TB. There were no differences in serum chemokine production and proviral load across TB groups stratified on HTLV-1 clinical status. In conclusion, TB may influence the development of HAM/TSP, and patients with these two diseases have an impairment in the modulation of immune response.

Keywords: HTLV-1; immune response; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

<b>FIG. 1.</b>
FIG. 1.
IFN-γ/IL-10 and TNF/IL-10 ratios from HTLV-1 carriers, probable HAM/TSP and HAM/TSP patients. The cytokine ratios are calculated with values of spontaneous cytokine production from HTLV-1 carriers (A and B), probable HAM/TSP patients (C and D) and HAM/TSP patients (E and F) stratified by TB status: no history of TB (TB− group), LTB, and history of TB (TB+). Statistical analysis is by Kruskal–Wallis test with post-test. HAM, HTLV-1-associated myelopathy; HTLV-1, human T cell lymphotropic virus type 1; IFN-γ, interferon-gamma; LTB, latent TB group; TB, tuberculosis; TNF, tumor necrosis factor-alpha; TSP, tropical spastic paraparesis.
<b>FIG. 2.</b>
FIG. 2.
Serum chemokine production from HTLV-1 carriers, probable HAM/TSP and HAM/TSP patients. The serum CXCL9 and CXCL10 levels were evaluated in HTLV-1 carriers (A and B), probable HAM/TSP patients (C and D) and HAM/TSP patients (E and F) stratified by TB status: TB negative; LTB; and TB+ group. Statistical analysis is by Kruskal–Wallis test with post-test.
<b>FIG. 3.</b>
FIG. 3.
Proviral load determination in HTLV-1 carriers, probable HAM/TSP and HAM/TSP patients. The proviral load was determined in HTLV-1 carriers (A), probable HAM/TSP patients (B) and HAM/TSP patients (C) stratified on TB status: TB negative, LTB and TB+ group. Statistical analysis is by Kruskal–Wallis test with post-test.

Similar articles

Cited by

References

    1. Gessain A, Barin F, Vernant JC, et al. : Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2:407–410 - PubMed
    1. Osame M, Usuku K, Izumo S, et al. : HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;1:1031–1032 - PubMed
    1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980;77:7415–7419 - PMC - PubMed
    1. Dourado I, Alcantara LC, Barreto ML, da Gloria Teixeira M, Galvao-Castro B: HTLV-I in the general population of Salvador, Brazil: A city with African ethnic and sociodemographic characteristics. J Acquir Immune Defic Syndr 2003;34:527–531 - PubMed
    1. Catalan-Soares B, Carneiro-Proietti AB, Proietti FA: Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): Serological screening prevalence rates in blood donors from large urban areas in Brazil. Cad Saude Publica 2005;21:926–931 - PubMed